Author: admin

Kidney Cancer Meeting Lyon, France 2015: Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON

Kidney Cancer Meeting Lyon, France 2015: Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? The Oncologists view Viktor Grünwald

Kidney Cancer Meeting Lyon, France 2015:Have Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? Axel Bex, The Netherlands Cancer Institute Amsterdam, The Netherlands

Kidney Cancer Meeting Lyon, France 2015: Should we push for even more minimal invasive and conservative approaches in kidney cancer? The view of the medical oncologist. Manuela Schmidinger, Medical University of Vienna Austria

Kidney Cancer Meeting Lyon, France 2015: Should we push even more for minimal invasive and conservative approaches in kidney cancer? Antonio Alcaraz Hospital Clínic Barcelona

Kidney Cancer Meeting Lyon, France 2015: Should We Now Biopsy Every Single Renal Tumor Before Treating? Bernard Escudier Institut Gustave Roussy Villejuif, France

Kidney Cancer Meeting Lyon, France 2015: SHOULD WE NOW BIOPSY EVERY SINGLE RENAL TUMOR BEFORE TREATING ? Alessandro VOLPE, M.D. University of Eastern Piedmont – Maggiore della Carità Hospital Novara, Italy

Kidney Cancer Meeting Lyon, France 2015: John Fitzpatrick Tribute: Life in the Fast Lane

Kidney Cancer Meeting Lyon, France 2015: Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology, MD Anderson

Kidney Cancer Meeting Lyon, France 2015: Clinical Relevance of Cancer Gene, James Brugarolas M.D., Ph.D. Kidney Cancer Program Leader Virginia Murchison Linthicum Endowed Scholar Associate Professor of Internal Medicine & Developmental Biology University of Texas Southwestern Medical Center

Kidney Cancer Meeting Lyon, France 2015: Tribute to Pieter De Mulder by Hein Van Poppel Professor and Chairman UZ Leuven Adjunct Secretary General EAU. Nephron Sparing SurgeryPast, Present and Future

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the key challenges in the manufacture, development and approval of biosimilars for breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses his highlights from the 14th St. Gallen International Breast Cancer Conference 2015. In addition, he provides an update on the novel combination antiemetic, netupitant and palonosetron (NEPA), for the prevention of chemotherapy-induced nausea and vomiting, and prospective opportunities and challenges for managing breast cancers with a focus on adjuvant therapies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Geoff Lindeman (The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) discusses the importance of the new therapeutic targets of BCL-2, BH3 mimetics, in oestrogen receptor-positive (ER+) breast cancer, including the challenges in the development process and use in clinical practice. Preclinical models of ER+ breast cancer demonstrate that BH3 mimetics combined with tamoxifen improves the effectiveness of hormone therapy. Clinical studies of the BH3 mimetic, ABT-199, are beginning in ER+ breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding of the current state of the biosimilar market as well as future challenges of the development and regulation of biosimilars. Biosimilars, which are biological products that demonstrate no clinically meaningful differences to an approved biological product, are currently approved in several areas of the world, and the biosimilars development pipeline is relatively large.European Medical JournalWebsite: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

This is my interview with Jeri Francoeur, Breast Cancer Patient Advocate, breast cancer survivor, and President of the Susan G Komen Chapter in Central Florida.

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development of the cyclin-dependent kinases (CDKs) 4 and 6 inhibitor, palbociclib, for breast cancer treatment. The phase 2 PALOMA-1 trial showed that the addition of palbociclib to letrozole significantly increased the progression-free survival versus letrozole alone in oestrogen receptor-positive, HER2-negative metastatic breast cancer. Subsequently, palbociclib received accelerated approval as frontline treatment for this patient population. Current trials are investigating palbociclib in other areas of breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference (SG-BCC) 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how mining big data can complement research approaches and improve patient care in cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses his study on the influence of cut points in the proliferation marker, Ki67, for clinical decision making in breast cancer patients, and suggests that Ki67 could be used as a continuous marker in this setting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint for survival, pathological complete response (pCR), in neoadjuvant studies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses the opportunities and challenges of developing new agents for breast cancer treatment, including optimising the use of drugs that target genetically defined breast cancer and the integration of these approaches. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the use of electronic medical records as a source of ‘big data’ that could potentially transform healthcare. CancerLinQ is one initiative that is aiming to aggregate and analyse data collected from patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses the clinical relevance of a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how prospective randomised trials in breast cancer treatment can adapt to the modern healthcare landscape. There is a promising potential for electronic medical records to provide data that is complementary to randomised trials, thereby improving research approaches in cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss recent advances in the management of patients with mantle cell lymphoma, including maintenance treatment and the development of personalised medicine. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss novel therapies and the future of chemotherapy-based regimens for the management of patients with relapsed or refractory mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

What should be the protocol for a rising PSA in an undiagnosed patient? Dr. Geo Espinosa of NYU-Langone Medical Center lays out the desired pathway in the context of patient-centric holistic uro-oncology.

Dr Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) provides an overview of immune approaches for the treatment of breast cancer at the 14th St. Gallen International Breast Cancer Conference 2015, including: The prognostic influence of tumour-infiltrating lymphocytes; Ongoing clinical trials of targeted therapies that modulate the immune system the PD-1 inhibitor, pembrolizumab, for triple-negative breast cancer, and the combination of trastuzumab and PD1-inhibitor for HER2-positive breast cancer; Tumour antigen cancer vaccines and ductal carcinoma in situ (DCIS). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses personalised genomic medicine for breast cancer, including the challenges of designing meaningful clinical trials to identify novel and relevant genetic disease biomarkers and the requirement for collaboration by multidisciplinary teams. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Geo Espinosa of NYU-Langone Medical Center explains the concept of Integrative Urology – the union of traditional and complementary standards of care to provide a more holistic, patient-centric modality.

Dr. Lluis Cecchini of the Hospital del Mar in Barcelona talks about the necessity for patients to become more involved in the management of their disease.

The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological training center. Dr. Albert Frances explains the program elements.

The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological training center.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical relevance of molecularly distinct subtypes of DLBCL. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigators choice in relapsed or refractory mantle cell lymphoma, including the study design; efficacy and safety endpoints; and conclusions. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) discusses novel biologic therapies for the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

http://cancerGRACE.org/ Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses novel therapeutic combinations that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) discusses novel therapies for mantle cell lymphoma, including biologic approaches with lenalidomide plus rituximab, ibrutinib and ABT-199. This programme has been supported by sponsorship from Celgene

Ted Okon Executive Director of COA conducts an interview with Author Siddhartha Mukherjee, MD and Producer/Director Barak Goodman about the Ken Burns PBS special Cancer:The Emperor of All Maladies. On PBS March 30th, 31st, and April 1st 2015

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses how the increased interaction between basic scientists, clinicians and patients is improving cancer medicine.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses TRAcking Cancer Evolution through therapy (TRACERx), which is a study that defines lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses how we may be able to anticipate tumour evolutionary trajectories for a more proactive approach in clinical practice.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses the collaboration between University College London and the Francis Crick Institute that is hoped to increase the interaction between academia and industry.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses the importance of understanding the genetic changes of tumour evolution for the development of more effective management options that are tailored to individual genetic profiles this is termed precision medicine.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses recent advances in the management of ovarian cancer, including the use of the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, as maintenance therapy for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.

Reports emerging data about molecular subtyping of early-stage breast cancer and patients’ risk of disease recurrence Steven C. Shivers, PhD., Charles E. Cox, MD,